Division
- Immunobiology
Twitter Handle
Research Areas of Interest
- Resistance to immune checkpoint therapies and cancer vaccines
Publications
| Sultan H, Salazar AM, Celis E. Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol. 2020 Jun;49:101414. doi: 10.1016/j.smim.2020.101414. Epub 2020 Oct 1. PMID: 33011064. |
| Sultan H, Fesenkova VI, Addis D, Fan AE, Kumai T, Wu J, Salazar AM, Celis E. Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol Immunother. 2017 Feb;66(2):203-213. doi: 10.1007/s00262-016-1834-5. Epub 2016 Apr 6. PMID: 27052572; PMCID: PMC5053837. |
| Sultan H, Kumai T, Nagato T, Wu J, Salazar AM, Celis E. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol Immunother. 2019 Mar;68(3):455-466. doi: 10.1007/s00262-018-02294-5. Epub 2019 Jan 2. PMID: 30604041; PMCID: PMC6428613. |
| Sultan H, Wu J, Fesenkova VI, Fan AE, Addis D, Salazar AM, Celis E. Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J Immunother Cancer. 2020 Sep;8(2):e001224. doi: 10.1136/jitc-2020-001224. PMID: 32958686; PMCID: PMC7507896. |
| Kumai T, Lee S, Cho HI, Sultan H, Kobayashi H, Harabuchi Y, Celis E. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses. Cancer Immunol Res. 2017 Jan;5(1):72-83. doi: 10.1158/2326-6066.CIR-16-0194. Epub 2016 Dec 9. PMID: 27941004; PMCID: PMC5221568. |
| Sultan H, Trillo-Tinoco J, Rodriguez P, Celis E. Effective antitumor peptide vaccines can induce severe autoimmune pathology. Oncotarget. 2017 Jul 29;8(41):70317-70331. doi: 10.18632/oncotarget.19688. PMID: 29050282; PMCID: PMC5642557. |
Assistant
Jeanne Grigsby
314-747-0561
jmgrigsby@wustl.edu
Lab Phone: 314-362-8746
Office Location: BJC-IH Building, Office Suite C 8417